City of Hope’s Department of Stem Cell Biology and Regenerative Medicine received a $4.9 million grant from the California Institute for Regenerative Medicine to train scientists in basic stem cell research and its clinical translation.
A Harvard and Massachusetts General Hospital study found that an artificial intelligence model incorporating multiple methods of machine learning accurately detects thyroid cancer and predicts pathological and genomic outcomes through analysis of routine ultrasound images.
A phase II trial led by University of Michigan researchers found that PET scans obtained before and midway through treatment for p16-positive oropharynx cancer (OPC) can help determine whether a patient can receive a lower dose of radiation therapy in the second half of their treatment course without compromising cancer control.
A multi-institutional study demonstrated that a blood test to detect circulating tumor DNA can accurately predict recurrence of HPV-driven oropharyngeal cancer following treatment. Results also indicated that the biomarker test may detect recurrent disease earlier than imaging or other standard methods of post-treatment surveillance.
Researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine and Memorial Sloan Kettering Cancer Center showed that a small group of chronic lymphocytic leukemia patients experienced treatment-resistant mutations in a clinical trial for Loxo-305 (pirtobrutinib).
The Pathology Department at Massachusetts General Hospital and Lunaphore, a Swiss life sciences company, entered a collaboration to develop an in vitro diagnostic that evaluates sensitivity of solid tumors to poly-ADP ribose polymerase inhibitors, with an initial focus on ovarian, breast, and prostate cancers.
The COVID-19 pandemic disrupted cancer screening and treatment and exacerbated health disparities, but also created unexpected opportunities in cancer research and care, a recent report from the American Association for Cancer Research states.
Ben Ho Park, Cornelius Abernathy Craig Professor of Medicine and deputy director of the Vanderbilt-Ingram Cancer Center, was named the center’s new director.
Ross Levine was named deputy physician-in-chief of translational research at Memorial Hospital, the main Manhattan hospital for Memorial Sloan Kettering Cancer Center.
The U.S, Senate Feb. 15 voted 50-46 to confirm Robert Califf as the next commissioner of FDA.
